JP6356217B2 - 胃癌に対する予後予測模型の製造方法 - Google Patents

胃癌に対する予後予測模型の製造方法 Download PDF

Info

Publication number
JP6356217B2
JP6356217B2 JP2016506253A JP2016506253A JP6356217B2 JP 6356217 B2 JP6356217 B2 JP 6356217B2 JP 2016506253 A JP2016506253 A JP 2016506253A JP 2016506253 A JP2016506253 A JP 2016506253A JP 6356217 B2 JP6356217 B2 JP 6356217B2
Authority
JP
Japan
Prior art keywords
group
gene
gastric cancer
expression
mrna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016506253A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016515390A5 (enExample
JP2016515390A (ja
Inventor
ヨン−ミン・フ
スン・フン・ノ
ジン・サック・ス
ジェ−ホ・チョン
ウン・スン・パク
Original Assignee
ノヴォミクス・カンパニー・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノヴォミクス・カンパニー・リミテッド filed Critical ノヴォミクス・カンパニー・リミテッド
Publication of JP2016515390A publication Critical patent/JP2016515390A/ja
Publication of JP2016515390A5 publication Critical patent/JP2016515390A5/ja
Application granted granted Critical
Publication of JP6356217B2 publication Critical patent/JP6356217B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/30—Unsupervised data analysis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Data Mining & Analysis (AREA)
  • Theoretical Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Databases & Information Systems (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Software Systems (AREA)
  • Artificial Intelligence (AREA)
  • Evolutionary Computation (AREA)
  • Bioethics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
JP2016506253A 2013-04-05 2014-04-07 胃癌に対する予後予測模型の製造方法 Expired - Fee Related JP6356217B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2013-0037336 2013-04-05
KR1020130037336A KR101501826B1 (ko) 2013-04-05 2013-04-05 위암에 대한 예후 예측 모형의 제조방법
PCT/KR2014/002959 WO2014163445A1 (ko) 2013-04-05 2014-04-07 위암에 대한 예후 예측 모형의 제조방법

Publications (3)

Publication Number Publication Date
JP2016515390A JP2016515390A (ja) 2016-05-30
JP2016515390A5 JP2016515390A5 (enExample) 2017-03-23
JP6356217B2 true JP6356217B2 (ja) 2018-07-11

Family

ID=51658661

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016506253A Expired - Fee Related JP6356217B2 (ja) 2013-04-05 2014-04-07 胃癌に対する予後予測模型の製造方法

Country Status (6)

Country Link
US (1) US20160040253A1 (enExample)
EP (1) EP2982986B1 (enExample)
JP (1) JP6356217B2 (enExample)
KR (1) KR101501826B1 (enExample)
CN (1) CN105431738B (enExample)
WO (1) WO2014163445A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109923121B (zh) * 2016-11-22 2022-12-23 武汉华大吉诺因生物科技有限公司 多肽及其应用
CN109952308B (zh) * 2016-11-29 2022-09-23 武汉华大吉诺因生物科技有限公司 多肽及其应用
KR102127449B1 (ko) * 2017-02-08 2020-06-26 사회복지법인 삼성생명공익재단 생존율 예측 모델 생성 방법, 장치 및 컴퓨터 프로그램
CN108504732A (zh) * 2017-02-27 2018-09-07 复旦大学附属华山医院 一种建立胃癌的风险预测模型的方法
KR101940657B1 (ko) * 2017-04-24 2019-01-21 (주) 노보믹스 위암의 생물학적 특성에 기반한 군 구분 및 예후 예측 시스템
CN107090503B (zh) * 2017-04-27 2020-06-19 元码基因科技（北京）股份有限公司 探针组合物、基因捕获芯片、试剂盒及其应用
CN107641653B (zh) * 2017-10-20 2021-02-19 南方医科大学南方医院 Macc1-as1探针在制备用于预测胃癌临床预后的诊断试剂中的应用
CN113851185B (zh) * 2021-11-29 2022-04-19 求臻医学科技（北京）有限公司 一种用于非小细胞肺癌患者免疫治疗的预后评估方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2537633T3 (es) * 2004-03-02 2015-06-10 The Johns Hopkins University Mutaciones del gen de PIK3CA en cánceres humanos
WO2007081720A2 (en) * 2006-01-05 2007-07-19 The Ohio State University Research Foundation Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
CA2648021A1 (en) * 2006-03-31 2007-10-11 Ordway Research Institute, Inc. Prognostic and diagnostic method for cancer therapy
NZ576852A (en) * 2006-10-26 2012-02-24 Genentech Inc Genetic variations (in the phosphatidylinositol 3-kinase regulatory subunit 1 pik3r1 protein) associated with tumors and method of testing for
CA2724348A1 (en) * 2008-05-15 2009-11-19 University Of Southern California Genotype and expression analysis for use in predicting outcome and therapy selection
KR20120061010A (ko) * 2010-11-02 2012-06-12 서울대학교산학협력단 위암 진단 방법
CN103459597B (zh) * 2010-12-13 2016-03-30 社会福祉法人三星生命公益财团 用于预测胃癌预后的标记和使用该标记预测胃癌预后的方法
SG2014010276A (en) * 2011-08-18 2014-03-28 Nestec Sa Compositions and methods for detecting allelic variants

Also Published As

Publication number Publication date
EP2982986A4 (en) 2016-12-07
KR101501826B1 (ko) 2015-03-13
EP2982986A1 (en) 2016-02-10
EP2982986B1 (en) 2019-01-30
WO2014163445A1 (ko) 2014-10-09
US20160040253A1 (en) 2016-02-11
CN105431738B (zh) 2017-11-03
CN105431738A (zh) 2016-03-23
JP2016515390A (ja) 2016-05-30
KR20140121524A (ko) 2014-10-16

Similar Documents

Publication Publication Date Title
JP6356217B2 (ja) 胃癌に対する予後予測模型の製造方法
CA2776751C (en) Methods to predict clinical outcome of cancer
CA2852098C (en) Colorectal cancer associated circulating nucleic acid biomarkers
JP2020031642A (ja) 遺伝子発現を用いた前立腺癌の予後を定量化する方法
JP2014509189A (ja) 結腸ガン遺伝子発現シグネチャーおよび使用方法
KR20080065476A (ko) 폐암 환자 또는 폐암 치료를 받은 폐암 환자에 대한 폐암재발의 위험을 예측하는 방법, 폐암 환자 또는 폐암 치료를받은 환자의 폐암 재발 위험성에 대한 보고서를 작성하는방법, 그에 의하여 작성된 보고서, 폐암 환자 또는 폐암치료를 받은 폐암 환자의 폐암 재발 위험을 진단하기 위한조성물, 키트 및 마이크로어레이
CN104903468A (zh) 用于帕金森氏病的新诊断MiRNA标志物
WO2017223216A1 (en) Compositions and methods for diagnosing lung cancers using gene expression profiles
US9890430B2 (en) Copy number aberration driven endocrine response gene signature
EP3638787A1 (en) Diagnostic, prognostic and therapeutic uses of long noncoding rnas for pathologies and toxicities inducing heart disorders
JP2014503221A (ja) 結腸直腸がんの再発予測のためのバイオマーカー
WO2017112738A1 (en) Methods for measuring microsatellite instability
CN116157539A (zh) 循环肿瘤核酸分子的多模态分析
CA2696947A1 (en) Methods and tools for prognosis of cancer in er- patients
CN104428426B (zh) 多发性硬化的诊断miRNA概况
JP2012513752A (ja) 結腸直腸癌細胞を含む試料を型判別するための方法および手段
WO2023152568A2 (en) Compositions and methods for characterizing lung cancer
JP6066116B2 (ja) 個体が大腸癌に罹患する可能性をｉｎｖｉｔｒｏで決定するための方法及びキット
JP2021503921A (ja) 癌を性質決定する組成物および方法
EP1683862B1 (en) Microarray for assessing neuroblastoma prognosis and method of assessing neuroblastoma prognosis
CN108103064B (zh) 长链非编码rna及其应用
KR101504818B1 (ko) 위암에 대한 예후 예측 시스템
US20160312289A1 (en) Biomolecular events in cancer revealed by attractor molecular signatures
CN114634982A (zh) 一种检测多核苷酸变异的方法
CN107974486A (zh) 一种乳腺癌术后复发风险检测方法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151203

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160916

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161216

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20170213

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20170627

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170724

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171024

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171225

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180521

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180613

R150 Certificate of patent or registration of utility model

Ref document number: 6356217

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees